Related Experiment Video
Updated: Jun 20, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Pemetrexed for the treatment of non-small-cell lung cancer
Christian Manegold1, Gerald Schmid-Bindert, Lothar R Pilz
1Chirurgische Universitätsklinik Mannheim-Interdisziplinäre Thorakale Onkologie, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany. prof.manegold@t-online.de
Abstract:
Pemetrexed is a novel multi-targeted antifolate that is used in the treatment of both malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC). Lung cancer is the most common cancer in the world and NSCLC represents approximately 80% of all lung cancers. Pemetrexed is the first NSCLC drug for which 'treatment-by-histology' has been determined. This refers to the greater efficacy of pemetrexed in patients with advanced NSCLC other than of predominantly squamous-cell histology. The advent of treatment-by-histology represents a significant step forward in the treatment of lung cancer, allowing physicians to tailor therapies to the individual patient. Ongoing trials aim to establish the place of pemetrexed in maintenance, in combination with other 'targeted agents', in adjuvant therapy in early NSCLC and in concurrent radio/chemotherapy.
